Modus Therapeutics Holding (MODTX.ST) Stock Analysis & AI Equity Report
Modus Therapeutics Holding (MODTX.ST) overview
Modus Therapeutics Holding (MODTX.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Modus Therapeutics Holding reported revenue of SEK 0m and operating profit of SEK -18.2m; the year-end share price was 0.30 SEK and market capitalisation was SEK 19.0m. Modus Therapeutics Holding is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Modus Therapeutics Holding's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-21. Data will be refreshed during report generation.
About Modus Therapeutics Holding
Modus Therapeutics Holding AB is a Swedish biotechnology company developing sevuparin, a proprietary polysaccharide candidate, for diseases with severe inflammatory components. Its research focuses on sepsis and septic shock, severe malaria, and anemia linked to chronic inflammation, including kidney disease. The company aims to advance development through clinical data and partnerships.
Generate the Modus Therapeutics Holding report
Modus Therapeutics Holding is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Modus Therapeutics Holding and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.